Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$360.85
▲ $0.88 (+0.2%)
Market data updated: 09/27 06:13 PM
Fundamentals updated: 09/27/2026
News analyzed: 09/27/2026
Market Cap
$533.38B
Day Range
$358.51 - $365.00
52-Week Range
$253.95 - $385.22
Beta
—
Next Earnings
04.11.2026
Support
$303.08
Resistance
$380.00
ONC is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+9.8% (1Y)
Strengths: 21/32 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 40.2%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $18.69 vs. price $360.85 (-94.8%)
Fair Value
Signal tension
Growth scores strong (82/100), but fair-value analysis scores this stock as relatively expensive (33/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
The overall investor score of 64, reflected by a MODERATE rating, results from a mixed picture across multiple dimensions. Growth stands out with double‑digit percentage increases in revenue (40.2%), EPS (140.4%), free cash flow (248.7%) and net income (144.5%), suggesting robust top‑ and bottom‑line expansion. However, valuation is severely off‑base: the stock trades at $366.73 versus an estimated fair value of $18.69 (a -94.9% gap) and carries an extreme P/E of 1,930.2, indicating likely overpricing. Technically, the price remains above both the 50‑day and 200‑day averages, yet the 50‑day SMA has just crossed below the 200‑day SMA, while a negative MACD histogram and an RSI of 61 point to weakening momentum. Fundamentally, gross margin is exceptionally strong at 87.5%, but operating, net, ROE and ROA margins are weak, highlighting cost‑efficiency challenges. News sentiment is overwhelmingly positive, driven by FDA approvals and partnership extensions, while quality metrics show a stable operating margin and low leverage (debt/equity 0.23). Risk indicators are moderate, with a 2.4% ATR and a Calmar ratio of 0.50. Together, these factors balance strong growth and positive news against severe valuation concerns and mixed technical/fundamental signals, leading to the moderate overall assessment.
The stock trades above both the 50‑day and 200‑day moving averages, yet the 50‑day SMA has recently crossed below the 200‑day SMA, while the MACD histogram is negative and RSI sits near 61, indicating mixed price momentum.
Technical signals influence short‑term market sentiment and can foreshadow near‑term price movements.
Profitability is uneven: gross margin is exceptionally high at 87.5%, but operating margin (8.4%), net margin (5.4%), ROE (6.6%) and ROA (3.5%) are weak, suggesting cost and efficiency pressures.
Fundamental health determines the sustainability of earnings and long‑term shareholder value.
The company exhibits extraordinary growth rates, with revenue up 40.2%, EPS up 140.4%, free cash flow up 248.7% and net income up 144.5% year‑over‑year.
Strong growth drivers are key indicators of expanding operations and future value creation.
Valuation metrics show severe overpricing: the stock trades at $366.73 versus an estimated fair value of $18.69 (a -94.9% gap) and carries an extremely high P/E of 1,930.2, far above NAV per share of $2.91.
Significant valuation discount increases risk of price correction and limits upside potential.
Recent news includes FDA approval of a key HER2+ regimen, a reported golden cross pattern, and expanded partnerships for leukemia treatments, all viewed as positive catalysts.
Positive news can boost investor sentiment and provide short‑term price support.
Operating margin remains stable or improving, and the firm maintains a low debt/equity ratio of 0.23, indicating solid financial structure and margin resilience.
Quality metrics reflect the company's ability to generate sustainable earnings with manageable leverage.
Risk measures include a 2.4% ATR, low leverage (debt/equity 0.23), a healthy current ratio of 3.41, and a Calmar ratio of 0.50 (19.8% 3‑year annualized return vs. 39.4% max drawdown).
Understanding risk levels helps investors assess potential downside and return expectations.
StockIQ conclusion
ONC presents a mixed investment profile with exceptionally strong growth and positive news catalysts, yet it suffers from severe valuation overpricing and mixed technical/fundamental signals. The moderate investor score reflects these balancing factors, highlighting both upside potential from growth and considerable risk from overvaluation and technical weakness. Investors should weigh the robust growth trajectory against the high valuation discount and consider how future regulatory and technical developments may alter the current outlook.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
69
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
Not enough data yet to generate this synthesis.
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of September 24, 2026
Then
69
$365.00
Now
69
$360.85
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
82
Quality
63
Value
33
Momentum
88
Risk
62
Sentiment
86
Fundamental
61
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent coverage of BeOne Medicines has highlighted its FDA approval of a TEVIMBRA‑based first‑line regimen for HER2+ gastric cancer, a renewed partnership with the Max Foundation to expand BRUKINSA access in low‑ and middle‑income countries, and a clinical collaboration with Revolution Medicines for Asian market development. Analyst coverage also features multiple buy/outperform ratings with updated price targets.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about BeOne Medicines Ltd.. News trend score: 86. Reason: 8 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
35
🎯 Conviction (vs. Emotion)
44
Psychology
47
Fundamentals
61
Technical
88
Valuation
33
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
+29%
Market Narrative
74
Fundamental Reality
44
Narrative Gap
+30
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
Market behavior suggests the stock is in a state of Euphoria, driven by robust price momentum, perfect news sentiment, and a massive premium to its DCF fair value. Elevated Overconfidence and moderate FOMO scores reinforce a narrative that the rally will continue despite weak reality metrics. Herding activity is mild, as ONC outperforms its peer group even as broader declines persist. The key open question is whether the optimism embedded in the 79‑point narrative gap can be sustained absent stronger fundamental support.
Updated: 08/31/2026, 12:09 AM
What could change this?
📈 3D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 97/100
🔴 Weakest match
Jack Schwager — 23/100
🗣️ Why do they disagree?
Based on his documented principles, the model estimates that Walter Bagehot would view ONC favorably because its high score of 97 highlights strong liquidity and survival potential in a credit squeeze. Meanwhile, Morgan Housel’s score of 81 reflects a quiet compounder that a patient holder could stay with, while Philip Fisher’s 75 indicates exceptional company quality. In contrast, Benjamin Graham’s low score of 30 shows the stock fails most of his defensive criteria, and Howard Marks’s caution score of 37 flags a risky valuation combination, leading to divergent conclusions across the methodologies.
Walter Bagehot
Lombard Street (1873)
🟢 97
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟢 81
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 75
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟢 74
Reasonable capital-preservation profile
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 73
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 61
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 58
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 54
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 49
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 47
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 44
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 41
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 30
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 28
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 23
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Based on the last 285 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (9 bullish · 0 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
87.5%
Operating Margin
8.4%
Net Margin
5.4%
EBITDA Margin
11.0%
ROE
6.6%
ROA
3.5%
ROIC
—
EPS
$0.20
Cash
$4.55B
Total Debt
$1.02B
Current Ratio
3.41
Debt/Equity
0.23
How is Fair Value calculated? →
Current Price
$360.85
Estimated Fair Value (DCF)
$18.69
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-94.8%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $1.18B | $1.08B |
| 2 | 19.4% | $1.41B | $1.18B |
| 3 | 13.8% | $1.60B | $1.23B |
| 4 | 8.1% | $1.73B | $1.22B |
| 5 | 2.5% | $1.77B | $1.15B |
Base FCF (last actual year)
$941.74M
Terminal Value
$27.94B
Present Value of Terminal Value
$18.16B
Enterprise Value
$24.03B
Net Debt
$-3.53B
Equity Value
$27.56B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$2.96
Tangible Book Value per Share (Tangible NAV)
$2.91
Sentiment based on basic keywords (not AI) — 8 positive, 10 neutral, 2 negative out of the last 20 articles.
Benzinga · 17.9.2026
SeekingAlpha · 16.9.2026
SeekingAlpha · 14.9.2026
Benzinga · 10.9.2026
Simply Wall St. · 5.9.2026
Yahoo · 5.9.2026
Simply Wall St. · 5.9.2026
Yahoo · 5.9.2026
Insider Monkey · 4.9.2026
Yahoo · 4.9.2026
Yahoo · 1.9.2026
Insider Monkey · 1.9.2026
Zacks · 1.9.2026
Yahoo · 1.9.2026
Yahoo · 1.9.2026
Business Wire · 1.9.2026
Benzinga · 1.9.2026
Yahoo · 31.8.2026
Business Wire · 31.8.2026
Benzinga · 31.8.2026
BeOne Medicines Ltd. (ONC) currently has a StockIQ AI score of 69/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ONC currently scores 69/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ONC's estimated fair value is $18.69, which is 94.8% below the current price of $360.85. This is one valuation model among several signals in the fair-value category, not a price target.
ONC's technical score is 88/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 40.2%; Earnings per share (EPS) growth: 140.4%; Free cash flow growth: 248.7%.
Based on the real signals StockIQ computed: Estimated fair value: $18.69 vs. price $360.85 (-94.8%); P/E: 1899.2; Operating margin: 8.4% — weak.
StockIQ has no recorded dividend payment history for ONC.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 21 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Wang Xiaodong | Open Market Sale | 8.9.2026 | 6,079 | -1,181 | $345.38 |
| Wang Xiaodong | Open Market Sale | 8.9.2026 | 12,847 | -10,688 | $349.28 |
| Wang Xiaodong | Open Market Sale | 8.9.2026 | 1,721 | -1,517 | $347.39 |
| Wang Xiaodong | Open Market Sale | 8.9.2026 | 0 | -1,721 | $348.01 |
| Wang Xiaodong | Open Market Sale | 8.9.2026 | 6,278 | -6,569 | $350.27 |
| Wang Xiaodong | Exercise of Derivative Securities | 8.9.2026 | 31,027 | +31,027 | $36.90 |
| Wang Xiaodong | Exercise of Derivative Securities | 8.9.2026 | 1,210,079 | -403,351 | — |
| Wang Xiaodong | Open Market Sale | 8.9.2026 | 23,535 | -7,492 | $348.31 |
| Wang Xiaodong | Open Market Sale | 8.9.2026 | 3,238 | -2,841 | $346.16 |
| Wang Xiaodong | Exercise of Derivative Securities | 8.9.2026 | 403,351 | -403,351 | — |
| Wang Xiaodong | Exercise of Derivative Securities | 8.9.2026 | 31,027 | +31,027 | $36.90 |
| Wang Xiaodong | Open Market Sale | 8.9.2026 | 6,278 | -6,278 | $351.25 |
| Wang Xiaodong | Open Market Sale | 8.9.2026 | 10,688 | -10,688 | $349.28 |
| Wang Xiaodong | Open Market Sale | 8.9.2026 | 6,569 | -6,569 | $350.27 |
| Wang Xiaodong | Open Market Sale | 8.9.2026 | 7,492 | -7,492 | $348.31 |
| Wang Xiaodong | Open Market Sale | 8.9.2026 | 2,841 | -2,841 | $346.16 |
| Wang Xiaodong | Open Market Sale | 8.9.2026 | 1,721 | -1,721 | $348.01 |
| Wang Xiaodong | Open Market Sale | 8.9.2026 | 1,517 | -1,517 | $347.39 |
| Wang Xiaodong | Open Market Sale | 8.9.2026 | 1,181 | -1,181 | $345.38 |
| Ball Titus B. | Open Market Sale | 1.9.2026 | 0 | -132 | $355.86 |
| Ball Titus B. | Open Market Sale | 1.9.2026 | 132 | -132 | $355.86 |
| Wu Xiaobin | Open Market Sale | 25.8.2026 | 280 | -280 | $380.00 |
| Wu Xiaobin | Open Market Sale | 25.8.2026 | 0 | -280 | $380.00 |
| OYLER JOHN | Open Market Sale | 12.8.2026 | 50,397 | -2,515 | $356.43 |
| OYLER JOHN | Open Market Sale | 12.8.2026 | 52,912 | -1,980 | $354.71 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
1,707,474 shares short as of 2026-09-15 · vs. 1,422,559 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
70.2% of trading volume this week was short selling, vs. 68.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology